{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:04:21Z","timestamp":1789697061186,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":84,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16349-9","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:31:38Z","timestamp":1782462698000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase II study of cabozantinib in metastatic or unresectable refractory gastrointestinal stromal tumour(GIST): a single-centre study from India"],"prefix":"10.1186","volume":"26","author":[{"given":"Neelima","family":"Ventrapragada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinjal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamim A.","family":"Shamim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivanand","family":"Gamanagatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajni","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihar Ranjan","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"5350","key":"16349_CR1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1126\/science.279.5350.577","volume":"279","author":"S Hirota","year":"1998","unstructured":"Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577\u201380.","journal-title":"Science"},{"issue":"23","key":"16349_CR2","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","volume":"21","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(23):4342\u20139.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"16349_CR3","doi-asserted-by":"publisher","unstructured":"Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, Lindner LH et al. Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(15):1713\u20131720. https:\/\/doi.org\/10.1200\/JCO.2016.71.0228. Epub 31 Mar 2017. PMID: 28362562.","DOI":"10.1200\/JCO.2016.71.0228"},{"key":"16349_CR4","unstructured":"US Food and Drug Administration. Stivarga. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203085s007lbl.pdf. Accessed 10 Feb 2026."},{"issue":"15suppl","key":"16349_CR5","doi-asserted-by":"publisher","first-page":"10524","DOI":"10.1200\/jco.2008.26.15_suppl.10524","volume":"26","author":"GD Demetri","year":"2008","unstructured":"Demetri GD, Huang X, Garrett CR, Sch\u00f6ffski P, Blackstein ME, Shah MH, et al. Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure. J Clin Oncol. 2008;26(15suppl):10524\u201310524.","journal-title":"J Clin Oncol"},{"issue":"10","key":"16349_CR6","first-page":"3034","volume":"8","author":"R Dagher","year":"2002","unstructured":"Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R. Approval summary: imatinib mesylate in the treatment of metastatic and\/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002;8(10):3034\u20138.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"16349_CR7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(4):626\u201332.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9440","key":"16349_CR8","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","volume":"364","author":"J Verweij","year":"2004","unstructured":"Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127\u201334.","journal-title":"Lancet"},{"issue":"33","key":"16349_CR9","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","volume":"26","author":"MC Heinrich","year":"2008","unstructured":"Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(33):5352\u20139.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"16349_CR10","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1158\/1078-0432.CCR-05-1211","volume":"12","author":"E Wardelmann","year":"2006","unstructured":"Wardelmann E, Merkelbach-Bruse S, Pauls K, Thomas N, Schildhaus HU, Heinicke T, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12(6):1743\u20139.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"16349_CR11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/path.2382","volume":"216","author":"B Liegl","year":"2008","unstructured":"Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008;216(1):64\u201374.","journal-title":"J Pathol"},{"issue":"22","key":"16349_CR12","doi-asserted-by":"publisher","first-page":"5745","DOI":"10.1158\/1078-0432.CCR-14-1397","volume":"20","author":"AP Garner","year":"2014","unstructured":"Garner AP, Gozgit JM, Anjum R, Vodala S, Schrock A, Zhou T, et al. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(22):5745\u201355.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"6","key":"16349_CR13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41416-019-0389-6","volume":"120","author":"C Serrano","year":"2019","unstructured":"Serrano C, Mari\u00f1o-Enr\u00edquez A, Tao DL, Ketzer J, Eilers G, Zhu M, et al. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2019;120(6):612\u201320.","journal-title":"Br J Cancer"},{"issue":"11","key":"16349_CR14","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1158\/1535-7163.MCT-18-1224","volume":"18","author":"T M\u00fchlenberg","year":"2019","unstructured":"M\u00fchlenberg T, Ketzer J, Heinrich MC, Grunewald S, Marino-Enriquez A, Trautmann M, et al. KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1\/2 Inhibition as Salvage Strategy. Mol Cancer Ther. 2019;18(11):1985\u201396.","journal-title":"Mol Cancer Ther"},{"issue":"9544","key":"16349_CR15","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329\u201338.","journal-title":"Lancet"},{"issue":"9863","key":"16349_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295\u2013302.","journal-title":"Lancet"},{"key":"16349_CR17","unstructured":"US Food and Drug Administration. Sutent. New York, NY: Pfizer Labs. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021938s13s17s18lbl.pdf. Accessed 10 Feb 2026."},{"key":"16349_CR18","unstructured":"US Food and Drug Administration. Ayvakit. Cambridge, MA: Blueprint Medicines Corp. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212608s000lbl.pdf. Accessed 10 Feb 2026."},{"issue":"10","key":"16349_CR19","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1093\/annonc\/mdy309","volume":"29","author":"ML Hemming","year":"2018","unstructured":"Hemming ML, Heinrich MC, Bauer S, George S. Translational insights into gastrointestinal stromal tumor and current clinical advances. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(10):2037\u201345.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"23","key":"16349_CR20","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","volume":"23","author":"CL Corless","year":"2005","unstructured":"Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(23):5357\u201364.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"34","key":"16349_CR21","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.22.00294","volume":"40","author":"S Bauer","year":"2022","unstructured":"Bauer S, Jones RL, Blay JY, Gelderblom H, George S, Sch\u00f6ffski P, et al. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2022;40(34):3918\u201328.","journal-title":"J Clin Oncol"},{"issue":"28","key":"16349_CR22","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1200\/JCO.21.00217","volume":"39","author":"YK Kang","year":"2021","unstructured":"Kang YK, George S, Jones RL, Rutkowski P, Shen L, Mir O, et al. Avapritinib versus regorafenib in locally advanced unresectable or metastatic gastrointestinal stromal tumor: a randomized, open-label phase III study. J Clin Oncol. 2021;39(28):3128\u201339.","journal-title":"J Clin Oncol"},{"issue":"7","key":"16349_CR23","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","volume":"21","author":"JY Blay","year":"2020","unstructured":"Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(7):923\u201334.","journal-title":"Lancet Oncol"},{"issue":"7","key":"16349_CR24","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1093\/annonc\/mdr598","volume":"23","author":"P Reichardt","year":"2012","unstructured":"Reichardt P, Blay JY, Gelderblom H, Schlemmer M, Demetri GD, Bui-Nguyen B, et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol Off J Eur Soc Med Oncol. 2012;23(7):1680\u20137.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"6","key":"16349_CR25","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1007\/s10637-012-9795-9","volume":"30","author":"SH Park","year":"2012","unstructured":"Park SH, Ryu MH, Ryoo BY, Im SA, Kwon HC, Lee SS, et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs. 2012;30(6):2377\u201383.","journal-title":"Invest New Drugs"},{"issue":"5","key":"16349_CR26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S1470-2045(16)00075-9","volume":"17","author":"O Mir","year":"2016","unstructured":"Mir O, Cropet C, Toulmonde M, Cesne AL, Molimard M, Bompas E, et al. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol. 2016;17(5):632\u201341.","journal-title":"Lancet Oncol"},{"issue":"12","key":"16349_CR27","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298\u2013308.","journal-title":"Mol Cancer Ther"},{"key":"16349_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejca.2020.04.021","volume":"134","author":"P Sch\u00f6ffski","year":"2020","unstructured":"Sch\u00f6ffski P, Mir O, Kasper B, Papai Z, Blay JY, Italiano A, et al. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 CaboGIST. Eur J Cancer. 2020;134:62\u201374.","journal-title":"Eur J Cancer"},{"issue":"5","key":"16349_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. JNCI J Natl Cancer Inst. 1993;85(5):365\u201376.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"6","key":"16349_CR30","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/sim.721","volume":"20","author":"RP A\u2019Hern","year":"2001","unstructured":"A\u2019Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med. 2001;20(6):859\u201366.","journal-title":"Stat Med"},{"issue":"12","key":"16349_CR31","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S1470-2045(13)70453-4","volume":"14","author":"YK Kang","year":"2013","unstructured":"Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1175\u201382.","journal-title":"Lancet Oncol"},{"key":"16349_CR32","first-page":"1497","volume":"17","author":"AK Baa","year":"2023","unstructured":"Baa AK, Rastogi S, Fernandes S, Shrivastava S, Yadav R, Barwad A, et al. Insights into the medical management of gastrointestinal stromal tumours: lessons learnt from a dedicated gastrointestinal stromal tumour clinic in North India. Ecancermedicalscience. 2023;17:1497.","journal-title":"Ecancermedicalscience"},{"issue":"6","key":"16349_CR33","doi-asserted-by":"publisher","first-page":"809","DOI":"10.4103\/ijmpo.ijmpo_45_20","volume":"41","author":"A Ramaswamy","year":"2020","unstructured":"Ramaswamy A, Chaudhari V, Bhargava P, Bhandare M, Kumar R, Shrikhande SV, Ostwal V. Gastrointestinal stromal tumor: an overview. Indian J Med Paediatr Oncol. 2020;41(6):809\u201318.","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"1","key":"16349_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","volume":"33","author":"PG Casali","year":"2022","unstructured":"Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2022;33(1):20\u201333.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"24","key":"16349_CR35","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1200\/JCO.2008.21.3330","volume":"27","author":"A Le Cesne","year":"2009","unstructured":"Le Cesne A, Van Glabbeke M, Verweij J, Casali PG, Findlay M, Reichardt P, et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(24):3969\u201374.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"16349_CR36","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1093\/annonc\/mdq696","volume":"22","author":"O Dudeck","year":"2011","unstructured":"Dudeck O, Zeile M, Reichardt P, Pink D. Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib. Ann Oncol Off J Eur Soc Med Oncol. 2011;22(8):1828\u201333.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"6","key":"16349_CR37","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/0284186X.2022.2068967","volume":"61","author":"A Kyriazoglou","year":"2022","unstructured":"Kyriazoglou A, Jespers P, Vandecavaye V, Mir O, Kasper B, Papai Z, et al. Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 CaboGIST. Acta Oncol. 2022;61(6):663\u20138.","journal-title":"Acta Oncol"},{"issue":"23","key":"16349_CR38","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","volume":"23","author":"CL Corless","year":"2005","unstructured":"Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23(23):5357\u201364.","journal-title":"J Clin Oncol"},{"issue":"5","key":"16349_CR39","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/j.1365-2559.2012.04300.x","volume":"61","author":"LA Doyle","year":"2012","unstructured":"Doyle LA, Nelson D, Heinrich MC, Corless CL, Hornick JL. Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study. Histopathology. 2012;61(5):801\u20139.","journal-title":"Histopathology"},{"issue":"7","key":"16349_CR40","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jamaoncol.2016.0256","volume":"2","author":"SA Boikos","year":"2016","unstructured":"Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon CB, George S, et al. Molecular Subtypes of KIT\/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol. 2016;2(7):922\u20138.","journal-title":"JAMA Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16349-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16349-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16349-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:51:20Z","timestamp":1789696280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16349-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16349"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16349-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8910891\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and its subsequent amendments, and was initiated after approval from the Institute Ethics Committee (IEC) for Post Graduate Research, All India Institute of Medical Sciences, New Delhi (IEC No. 455\/24.08.2023). The study was conducted prospectively following IEC approval and written informed consent was obtained from all participants prior to enrolment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent for publication of anonymized clinical information.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1119"}}